We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agios' Leukemia Drug Bodes Well for Growth & Strong Pipeline
Read MoreHide Full Article
On Apr 17, 2018, we issued an updated report on Agios Pharmaceuticals, Inc. (AGIO - Free Report) , a development-stage biopharmaceutical company focused on development of treatments for cancer and rare genetic metabolic disorders (RGD), a subset of orphan genetic metabolic diseases.
Shares of Agios have soared 51.9% so far this year, outperforming the industry’s increase of 2.8%.
Agios’ only marketed drug is Idhifa, which received an FDA approval last August for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation. The approval lent a huge boost to the company on the back of its immense commercial potential in the target market. Moreover, Idhifa provides a first-ever treatment, alternative to patients living with the aforementioned indication in the United States. Notably, Idhifa also enjoys an Orphan Drug status in the EU for treating AML.
Agios’ progress with the pipeline has been quite impressive. The company has some interesting candidates in its portfolio including an IDH1 mutant inhibitor, AG-120 (ivosidenib) and a pan-IDH mutant inhibitor, AG-881.
Ivosidenib is presently under priority review in the United States for treating patients with R/R AML with an IDH1 mutation. An approval for ivosidenib is expected in the third quarter of 2018. Additionally, the company anticipates a regulatory filing for the candidate in the EU in the fourth quarter of 2018 for the same indication.
Ivosidenib is also being evaluated in phase I study for addressing advanced hematologic malignancies and in phase I/II combined with Celgene’s Vidaza for the cure of newly diagnosed AML patients, who are not eligible for intensive chemotherapy.
Meanwhile, Agios is conducting phase I programs on AG-881 for treating patients with advanced IDH1 or IDH2 mutant-positive solid tumors including glioma. Last October, the company announced positive findings from the study.
Notably, the company also plans to initiate a perioperative window study to analyze ivosidenib and AG-881 in low grade glioma for investigating the effects on brain tumor tissue in the first half of 2018.
The company has another interesting candidate in its portfolio. Its lead rare genetic diseases candidate, AG-348, is under evaluation in a phase II trial on adult, transfusion-independent patients with Pyruvate kinase deficiency. Agios reported positive data from the program in June 2017. The FDA granted a fast track designation to the candidate for the given indication. As the RGD market is still untapped, newer therapies in this area hold huge potential.
Successful development and commercialization of the above investigational candidates should boost the company’s top line going forward, considering the lucrative markets that it is targeting.
Agios carries a Zacks Rank #3 (Hold). Two better-ranked stocks in the health care sector are Ligand Pharmaceuticals Incorporated (LGND - Free Report) and Infinity Pharmaceuticals, Inc. , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Ligand’s earnings per share estimates have moved north from $3.78 to $4.40 for 2018 and from $4.75 to $5.32 for 2019 in the last 60 days. The company delivered a positive surprise in three of the trailing four quarters with an average beat of 24.88%. Share price of the company has soared 62.8% over a year.
Infinity’s loss per share estimates have narrowed from $1.69 to 74 cents for 2018 and from 94 cents to 66 cents for 2019 in the last 60 days. The company pulled off a positive surprise in three of the trailing four quarters with an average beat of 7.87%.
Can Hackers Put Money INTO Your Portfolio?
Earlier this year, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Image: Bigstock
Agios' Leukemia Drug Bodes Well for Growth & Strong Pipeline
On Apr 17, 2018, we issued an updated report on Agios Pharmaceuticals, Inc. (AGIO - Free Report) , a development-stage biopharmaceutical company focused on development of treatments for cancer and rare genetic metabolic disorders (RGD), a subset of orphan genetic metabolic diseases.
Shares of Agios have soared 51.9% so far this year, outperforming the industry’s increase of 2.8%.
Agios’ only marketed drug is Idhifa, which received an FDA approval last August for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation. The approval lent a huge boost to the company on the back of its immense commercial potential in the target market. Moreover, Idhifa provides a first-ever treatment, alternative to patients living with the aforementioned indication in the United States. Notably, Idhifa also enjoys an Orphan Drug status in the EU for treating AML.
Agios’ progress with the pipeline has been quite impressive. The company has some interesting candidates in its portfolio including an IDH1 mutant inhibitor, AG-120 (ivosidenib) and a pan-IDH mutant inhibitor, AG-881.
Ivosidenib is presently under priority review in the United States for treating patients with R/R AML with an IDH1 mutation. An approval for ivosidenib is expected in the third quarter of 2018. Additionally, the company anticipates a regulatory filing for the candidate in the EU in the fourth quarter of 2018 for the same indication.
Ivosidenib is also being evaluated in phase I study for addressing advanced hematologic malignancies and in phase I/II combined with Celgene’s Vidaza for the cure of newly diagnosed AML patients, who are not eligible for intensive chemotherapy.
Meanwhile, Agios is conducting phase I programs on AG-881 for treating patients with advanced IDH1 or IDH2 mutant-positive solid tumors including glioma. Last October, the company announced positive findings from the study.
Notably, the company also plans to initiate a perioperative window study to analyze ivosidenib and AG-881 in low grade glioma for investigating the effects on brain tumor tissue in the first half of 2018.
The company has another interesting candidate in its portfolio. Its lead rare genetic diseases candidate, AG-348, is under evaluation in a phase II trial on adult, transfusion-independent patients with Pyruvate kinase deficiency. Agios reported positive data from the program in June 2017. The FDA granted a fast track designation to the candidate for the given indication. As the RGD market is still untapped, newer therapies in this area hold huge potential.
Successful development and commercialization of the above investigational candidates should boost the company’s top line going forward, considering the lucrative markets that it is targeting.
Agios Pharmaceuticals, Inc. Price and Consensus
Agios Pharmaceuticals, Inc. Price and Consensus | Agios Pharmaceuticals, Inc. Quote
Zacks Rank & Key Picks
Agios carries a Zacks Rank #3 (Hold). Two better-ranked stocks in the health care sector are Ligand Pharmaceuticals Incorporated (LGND - Free Report) and Infinity Pharmaceuticals, Inc. , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Ligand’s earnings per share estimates have moved north from $3.78 to $4.40 for 2018 and from $4.75 to $5.32 for 2019 in the last 60 days. The company delivered a positive surprise in three of the trailing four quarters with an average beat of 24.88%. Share price of the company has soared 62.8% over a year.
Infinity’s loss per share estimates have narrowed from $1.69 to 74 cents for 2018 and from 94 cents to 66 cents for 2019 in the last 60 days. The company pulled off a positive surprise in three of the trailing four quarters with an average beat of 7.87%.
Can Hackers Put Money INTO Your Portfolio?
Earlier this year, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>